-

Citi Appointed as Depositary Bank for Addex Therapeutics’ ADR Programme

LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Addex Therapeutics Ltd -- a clinical-stage pharmaceutical company -- to act as depositary bank for its American Depositary Receipt (“ADR”) programme.

Addex Therapeutics’ American Depositary Shares (“ADS”) trade on the Nasdaq Global Select Market under the symbol “ADXN”. Each ADS represents six ordinary shares of the company. Addex Therapeutics’ underlying ordinary shares are listed and trade on SIX Swiss Exchange under the same symbol “ADXN”.

“Listing on the Nasdaq is an important step in the evolution of Addex as we approach the start of the first pivotal registration clinical study for dipraglurant, and I thank the team at Citi for their contributions to this important milestone,” said Tim Dyer, CEO of Addex. “Today marks the beginning of a new chapter for Addex as we continue to execute on our strategy to build a sustainable pharmaceutical company focused on the promise of allosteric modulation for neurological disorders.”

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Addex Therapeutics’ Nasdaq listed ADR programme and further expand the company’s investor outreach through the expertise of our leading Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

About Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID) in Q1 2020.

About Citi
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Contacts

Susan Monahan
+44 (0) 20 7508 0786
susan.monahan@citi.com

Industry:

Citi

NYSE:C
Release Versions
English

Contacts

Susan Monahan
+44 (0) 20 7508 0786
susan.monahan@citi.com

More News From Citi

Citi Investor Services Wins US$380 Billion Middle Office Mandate from Aegon Asset Management

LONDON--(BUSINESS WIRE)--Citi Investor Services has been awarded a full middle office mandate by Aegon Asset Management (Aegon AM), covering US$380 billion in Assets under Management and extending a long-term relationship with a key client of 20 years. This mandate expands the scope of services already provided to Aegon AM by Citi, including custody, depositary, collateral, fund accounting and administration as well as transfer agency services. Citi has extended the breadth of its middle office...

Citi advised StepStone Group on landmark $3.3 billion Structured Solutions Vehicle

LONDON--(BUSINESS WIRE)--Citi has advised StepStone Group, a leading global private markets investment firm, on the structuring and placement of the largest structured solutions vehicle of its kind to date, resulting in $3.3 billion in commitments to invest predominantly in private market secondaries. The vehicle enables institutional investors to access the firm's secondaries platform through a flexible and capital-efficient solution. Harsh Shah, Head of Private Capital Solutions at Citi, comm...

Citi Becomes Clearing Member of London Precious Metals Clearing Limited

LONDON--(BUSINESS WIRE)--Citi and the LPMCL today announce Citi's admission as a clearing member of London Precious Metals Clearing Limited (LPMCL), adding Loco London settlement services for gold, silver, platinum and palladium. The new offering marks a major expansion of Citi Commodities’ global precious metals business as it delivers a more comprehensive product suite to its global client base. “Citi’s admission as a clearing member of LPMCL represents a natural extension of our long‑standin...
Back to Newsroom